Novartis innovates RNAi cholesterol-lowering drugs declared clinically in China.

On June 28, Novartis' clinical application for Inclisiran injection was accepted by CDE in ChinaThe drug is Novartis's $9.7 billion acquisition of The Medicines Company for a first-of-its-kind small-molecule interfering RNA (siRNA) cholesterol-lowering drug, which requires only twice a yearNovartis has filed an Inclisiran listing application with the FDA and EMAthree Phase III clinical trials published in NEJM (ORION-9, 10 and 11) showed that two inclisiran treatments per year, after two initial doses, were consistently and significantly reduced LDL-C compared to placebosInclisiran has good tolerance and safety is similar to placeboSource: NextPharmamore than 50 million patients worldwide with atherosclerosis cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) who are treated with secondary prophylaxis are not able to meet the control targets of low-density lipoprotein (LDL-C) through existing standard treatments and remain at increased cardiovascular riskInclisiran only needs to be injected twice a year and can significantly and consistently control LDL-C levels, facilitating patient adherence to treatment and helping patients keep cholesterol levels low at all times.